Insulet Resumes Omnipod Horizon Pivotal Trial

Insulet announced it has resumed the Omnipod Horizon pivotal trial. Recall, the trial was paused in early March 2020 following a software anomaly that could lead to “using an incorrect glucose value which has the potential to impact insulin delivery.” According to the press release, Insulet expects a US launch of Omnipod Horizon in H1 ’21, which is consistent with the timeline stated during the company’s Q1 ’20 earnings call. Below, FENIX provides insight on the potential impact of the delayed launch.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.